Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
HYDROQUINONE
Overview
What is OBAGI-C RX SYSTEM C-THERAPY?
Hydroquinone is 1,4-benzenediol. Hydroquinone occurs as fine, white needles. The drug is freely soluble in water and in alcohol. Chemically, hydroquinone is designated as p-dihydroxybenzene; the empirical formula is CHO; molecular weight is 110.11 g per mol.
The chemical structure is in the diagram.
What does OBAGI-C RX SYSTEM C-THERAPY look like?
What are the available doses of OBAGI-C RX SYSTEM C-THERAPY?
Sorry No records found.
What should I talk to my health care provider before I take OBAGI-C RX SYSTEM C-THERAPY?
Sorry No records found
How should I use OBAGI-C RX SYSTEM C-THERAPY?
The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.
A thin application should be applied once or twice daily or as directed by a physician. If no improvement is seen after three (3) months of treatment, use of this product should be discontinued. Sun exposure should be limited by using a sunscreen agent or protective clothing to cover bleached skin when using and after using this product in order to prevent darkening from reoccurring.
What interacts with OBAGI-C RX SYSTEM C-THERAPY?
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.
What are the warnings of OBAGI-C RX SYSTEM C-THERAPY?
Array
- •
- •
- •
- •
What are the precautions of OBAGI-C RX SYSTEM C-THERAPY?
(See
)
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.
Pregnancy
Nursing Mothers
It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.
Pediatric Usage
Safety and effectiveness in children, below the age of 12 years, have not been established.
What are the side effects of OBAGI-C RX SYSTEM C-THERAPY?
No systemic adverse reactions have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur, in which case the product should be discontinued and physician notified immediately.
To report SUSPECTED ADVERSE REACTIONS, contact Obagi Medical Products, a division of Valeant Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
What should I look out for while using OBAGI-C RX SYSTEM C-THERAPY?
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.
The Obagi-C
Rx System C-Therapy Night Cream contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
®
What might happen if I take too much OBAGI-C RX SYSTEM C-THERAPY?
Sorry No Records found
How should I store and handle OBAGI-C RX SYSTEM C-THERAPY?
Store at room temperature 15°-30°C (59°-86°F). Obagi-C Rx System C-Clarifying SerumObagi-C Rx System C-Clarifying SerumObagi-C Rx System C-Therapy Night CreamStore at controlled room temperature: 15° to 25°C (59° to 77°F). Keep out of direct sunlight.Obagi-C Rx System C-Clarifying SerumObagi-C Rx System C-Clarifying SerumObagi-C Rx System C-Therapy Night CreamStore at controlled room temperature: 15° to 25°C (59° to 77°F). Keep out of direct sunlight.Obagi-C Rx System C-Clarifying SerumObagi-C Rx System C-Clarifying SerumObagi-C Rx System C-Therapy Night CreamStore at controlled room temperature: 15° to 25°C (59° to 77°F). Keep out of direct sunlight.Obagi-C Rx System C-Clarifying SerumObagi-C Rx System C-Clarifying SerumObagi-C Rx System C-Therapy Night CreamStore at controlled room temperature: 15° to 25°C (59° to 77°F). Keep out of direct sunlight.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (DOPA) and suppression of other melanocyte metabolic processes. Exposure to sunlight or ultraviolet light will cause repigmentation of the bleached areas, which may be prevented by the use of sunscreen agents contained in the Obagi-C Rx System Sun Shield Matte Broad Spectrum SPF 50.
Non-Clinical Toxicology
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.The Obagi-C
Rx System C-Therapy Night Cream contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
®
See .
Array
(See )
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.
No systemic adverse reactions have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur, in which case the product should be discontinued and physician notified immediately.
To report SUSPECTED ADVERSE REACTIONS, contact Obagi Medical Products, a division of Valeant Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).